A Randomized, Parallel Group, Placebo-controlled, Multicenter Phase 3 Study With a PK Sub-group Study With Beclomethasone HFA at 400 μg and 800 μg Daily Doses Compared to Placebo and QVAR in Persistent Asthma.
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Beclometasone (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Adamis Pharmaceuticals Corporation
- 06 Feb 2019 Status changed from planning to not yet recruiting.
- 10 Aug 2018 According to an Adamis Pharmaceuticals Corporation media release, patient recruitment anticipated in Q4 2018.
- 10 May 2018 According to Adamis Pharmaceuticals Corporation media release, the company received approval for APC-1000 from the FDA to proceed with phase 3 clinical studies.The company expects to initiate this trial in 2018.